Skip Navigation

Brain 2007 130(5):1181-1182; doi:10.1093/brain/awm088
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Martin, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Martin, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author (2007). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Scientific Commentaries

Is haematopoietic stem cell transplantation a treatment option for severe MS or not?*

Roland Martin

Institute for Neuroimmunology and Clinical Multiple Sclerosis Research (inims), Center for Molecular Neurobiology Hamburg (ZMNH), University Medical Center Eppendorf, Falkenried 94, 20251 Hamburg, Germany

E-mail: roland.martin@zmnh.uni-hamburg.de

.

The first 10% of the full text of this article appears below.

A number of treatments are now available to treat multiple sclerosis (MS) among them several beta interferons (IFN-ß) and glatiramer acetate (GA) for relapsing–remitting MS (RR-MS), and mitoxantrone and natalizumab for aggressive forms of RR-MS and those patients who have failed the first line therapies IFN-ß and GA. With mitoxantrone and natalizumab, higher efficacy comes at the price of more and more severe adverse events among them secondary leukaemias and compromise of cardiac function (mitoxantrone), and progressive multifocal leukoencephalopathy (PML)(natalizumab). Numerous other therapies that fall in the latter category are currently in development including alemtuzumab (Campath-1), fingolimode (FTY-720), cladribine and others. . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 BrainHome page
R. A. Nash, O. Stuve, J. D. Bowen, E. M. Frohman, L. M. Griffith, G. J. Hutton, G. H. Kraft, U. Popat, M. K. Racke, and P. A. Muraro
Autologous HSCT for advanced MS: Is the glass half-empty or really half-full?
Brain, February 1, 2008; 131(2): e89 - e89.
[Full Text] [PDF]

Home page
 BrainHome page
I. Metz, C. F. Lucchinetti, H. Openshaw, A. Garcia-Merino, H. Lassmann, M. S. Freedman, B. Azzarelli, O. J. Kolar, H. L. Atkins, and W. Bruck
Autologous hematopoietic stem cell transplantation: the glass seems to be half full for aggressive, early forms of MS and half empty for advanced MS
Brain, February 1, 2008; 131(2): e90 - e90.
[Full Text] [PDF]